Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666060 | 1.00 | LMNA (0.57) | LMNAHPGDMCL1MAOBPTGER1 | |
| SCHEMBL21722682 | 0.93 | LMNA (0.57) | LMNAHPGDMCL1MAOBPTGER1 | |
| SCHEMBL6761438 | 0.85 | PTGER1 (0.56) | LMNAHPGDMCL1PTGER1MAPT | |
| SCHEMBL24983696 | 0.82 | LMNA (0.54) | LMNAHPGDMCL1MAOBTDP1 | |
| SCHEMBL15726040 | 0.81 | PTGER1 (0.57) | LMNAHPGDMCL1MAOBPTGER1 | |
| SCHEMBL6761520 | 0.81 | LMNA (0.52) | LMNAHPGDMCL1MAOBPTPN1 | |
| SCHEMBL12379065 | 0.81 | PTGER1 (0.53) | LMNAHPGDMCL1MAOBPTGER1 | |
| SCHEMBL17506130 | 0.80 | LMNA (0.57) | LMNAHPGDMCL1MAOBTDP1 | |
| SCHEMBL27489408 | 0.78 | MEN1 (0.63) | HPGDMCL1MAOBPTGER1SMN1; SMN2 | |
| SCHEMBL10604980 | 0.78 | LMNA (0.67) | LMNAHPGDMAOBMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320222-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2025-10-16 | — | — | US | disclosed |
| US-10954219-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-23 | — | — | US | disclosed |
| US-10954219-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3121175-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320222-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP3A7 | LMNA 1612/4885HPGD 207/4885MCL1 2351/4885 |
| US-20180282313-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | LMNA 4047/4885HPGD 2471/4885MCL1 471/4885 |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | LMNA 4047/4885HPGD 2471/4885MCL1 471/4885 |
| US-10017500-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | LMNA 4047/4885HPGD 2471/4885MCL1 471/4885 |
| US-10954219-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | LMNA 4047/4885HPGD 2471/4885MCL1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.